Watch: A Safe, Accessible Treatment for ME/CFS? The IVO-21 Study
Could IVO-21 Lead to a New ME/CFS Mitochondrial Treatment? In May 2026, Solve selected Dr. Jay H. Chung (National Institutes of Health) as a recipient of our latest ME/CFS Catalyst […]
The SIGNAL Study: Using Home-Based Treatments to Advance ME/CFS and Long Covid Research
What if we could learn faster which ME/CFS and Long Covid treatments work—and who they work for? Join members of the SIGNAL research team for a conversation about their Solve […]
Solve-Funded Phase 2 Observational Study Yields More Support for Repurposing Rapamycin to Reduce a Broad Range of ME/CFS Symptoms
Dr. Avik Roy is the chief scientific officer at the Simmaron Research Institute, a nonprofit organization that conducts research and observational studies on ME/CFS to find treatments for people with […]
A Safe, Accessible Treatment for ME/CFS? The Mitochondrial Stabilizer IVO-21 Study
As part of our commitment to advancing science that brings real hope to people living with ME/CFS or Long Covid, Solve has selected Dr. Jay H. Chung (National Institutes of […]
Sequence ME & Long Covid: The Search for ME/CFS and Long Covid Biomarkers and Subtypes
The DecodeME Project is the largest genetic study of ME/CFS conducted to date and has identified eight genetic signals where people with ME/CFS tend to differ from those without, linked […]
New Catalyst Award Funding From Solve M.E. Advances Innovative ME/CFS and Long Covid Studies Toward Treatments
In recognition of World ME Day, Solve M.E. announced today new funding for two award-winning research studies aimed at accelerating progress toward diagnostics and treatments for ME/CFS and Long Covid. […]
Webinar Replay: The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a […]
Why Public Comments Matter: How Solve Protects Patients Before Policies and Trials are Set in Stone
When an organization, like a government agency, company, or nonprofit, considers a big change or launches a new initiative, it may ask for feedback from the public during a public […]
The Discovery of Target Antigens for Dysfunctional T Cells in ME/CFS and Long COVID
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a […]
GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar […]
Solve CEO Emily Taylor Reflects On What We Built Together In 2025 and Why It Mattered
Dear Friends, As this year comes to a close, I find myself thinking not just about what we accomplished — but why it mattered. As a caregiver who understands how […]
Simmaron’s Solve ME/CFS Catalyst Award-Winning Rapamycin Trial Yields Promising Treatment Findings
Dr. Avik Roy is the chief scientific officer at the Simmaron Research Institute, a non-profit organization dedicated to understanding ME/CFS and related diseases and to treating people with these diseases. […]